COMMUNIQUÉS West-GlobeNewswire

CDT Equity Inc. Announces Reverse Stock Split
25/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reverse stock split of [...]
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
25/03/2026
Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 [...]
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
25/03/2026
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, [...]
Eascra Biotech Takes First Place at TechConnect Bio in Space Innovation Challenge
25/03/2026
Nanomedicine startup wins $30,000 prize for pioneering nanoparticle delivery platform BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Eascra Biotech , a nanomedicine startup, has won first place at the TechConnect Bio in [...]
Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis
25/03/2026
Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients with IPF BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company [...]
NANOBIOTIX Statement Regarding Recent Media Speculation
25/03/2026
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
25/03/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
SRx Health Solutions Hedges Decentralized Finance (DeFi) Portfolio with Investment in Gold and Reduces its Emerging Market Hedge
25/03/2026
NORTH PALM BEACH, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which [...]
Acentra Health Names New Senior Vice Presidents, Mohamed Karama and Nirav Dalal, to Drive Company Growth and Business Development
25/03/2026
Proven healthcare leaders to oversee growth, sales, and capture management, supporting the company’s mission of innovating solutions that accelerate better outcomes MCLEAN, Va., March 25, 2026 (GLOBE NEWSWIRE) -- [...]
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
25/03/2026
CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has completed its previously announced exchange offer to each holder of [...]
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
25/03/2026
FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the [...]
TOMI Environmental Solutions’ Binary Ionization Technology Approved in the Netherlands
25/03/2026
European Union Market Expansion Advances with Official Authorization FREDERICK, Md., March 25, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and [...]
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
25/03/2026
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a traditional upfront [...]
VIVUS Reinforces QSIVA®’s Clinical Efficacy and Safety in Obesity Management
25/03/2026
— QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a [...]
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
25/03/2026
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 [...]
Declaration de NANOBIOTIX concernant une recente rumeur mediatique
25/03/2026
PARIS, FRANCE; CAMBRIDGE, Massachusetts, 25 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, [...]
SEMCAP Launches SEMCAP Beauty & Wellness to Capitalize on Opportunities in Burgeoning Longevity and Consumer Wellbeing Space
25/03/2026
Consumer Products Industry Leader, Vasiliki Petrou, to Lead New Vertical Investment Strategy PHILADELPHIA and LONDON, March 25, 2026 (GLOBE NEWSWIRE) -- SEMCAP announces SEMCAP Beauty & Wellness to capitalize on [...]
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
25/03/2026
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary [...]
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
25/03/2026
Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financial results and [...]

Pages